newsfilter
← Latest News
GlobeNewswire·

Marker Therapeutics Reports Q3 2022 Operating and Financial Results

HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the